Standard BioTools Inc. Operating Lease, Payments
Standard BioTools Inc. (LAB) reported Operating Lease, Payments of $8.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-03-16
- Standard BioTools Inc. operating lease, payments for the quarter ending 2020-12-31 was $1.82M, a 93.83% increase year-over-year.
- Standard BioTools Inc. operating lease, payments for the quarter ending 2020-09-30 was $1.46M, a 44.59% increase year-over-year.
- Standard BioTools Inc. operating lease, payments for the quarter ending 2020-06-30 was $1.12M, a 7.29% increase year-over-year.
- Standard BioTools Inc. operating lease, payments for the quarter ending 2020-03-31 was $868.00K, a 14.73% decline year-over-year.
- Standard BioTools Inc. operating lease, payments for fiscal 2025 was $8.20M, a 2.01% increase from fiscal 2024.
- Standard BioTools Inc. operating lease, payments for fiscal 2024 was $8.04M, a 1.39% increase from fiscal 2023.
- Standard BioTools Inc. operating lease, payments for fiscal 2023 was $7.93M, a 5.19% increase from fiscal 2022.
- Standard BioTools Inc. operating lease, payments for fiscal 2022 was $7.54M, a 0.37% decline from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month | Operating Lease, Payments 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $8.20M 10-K · filed 2026-03-16 | ||||
| 2024-12-31 | $8.04M 10-K · filed 2026-03-16 | $9.92M 10-K · filed 2025-03-11 | |||
| 2023-12-31 | $7.93M 10-K · filed 2025-03-11 | ||||
| 2022-12-31 | $7.54M 10-K · filed 2024-03-01 | ||||
| 2021-12-31 | $7.57M 10-K · filed 2023-03-14 | ||||
| 2020-12-31 | $1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $3.28M derived: sum of 2 quarters · filed 2022-03-08 | $4.40M derived: sum of 3 quarters · filed 2022-03-08 | $5.26M 10-K · filed 2022-03-08 | |
| 2020-09-30 | $1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $2.58M derived: sum of 2 quarters · filed 2020-11-09 | $3.44M 10-Q · filed 2020-11-09 | $4.38M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2020-06-30 | $1.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $1.99M 10-Q · filed 2020-08-07 | $2.93M derived: sum of 3 quarters · filed 2021-02-25 | $3.93M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2020-03-31 | $868.00K 10-Q · filed 2020-05-11 | $1.81M derived: sum of 2 quarters · filed 2021-02-25 | $2.81M derived: sum of 3 quarters · filed 2021-02-25 | $3.86M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-12-31 | $940.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $1.95M derived: sum of 2 quarters · filed 2021-02-25 | $2.99M derived: sum of 3 quarters · filed 2021-02-25 | $4.01M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $1.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $2.05M derived: sum of 2 quarters · filed 2020-11-09 | $3.07M 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $2.06M 10-Q · filed 2020-08-07 | |||
| 2019-03-31 | $1.02M 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |